AbbVie Inks a Deal With Neomorph

AbbVie, Neomorph Strike Deal to Co-Develop Molecular Glue Degraders for Oncology, Immunology
Under terms of the deal, AbbVie will provide Neomorph with an upfront payment and the potential to earn up to $1.64 billion in milestone payments.
AbbVie Inks a Deal With Neomorph for Molecular Glue Degraders
AbbVie ABBV announced that it has entered into a collaboration and option-to-license agreement with the San Diego-based private biotech Neomorph to develop molecular glue degraders for multiple targets across oncology and immunology.
AbbVie and Neomorph enter molecular glue degrader partnership worth $1.64bn
AbbVie has partnered with Neomorph to develop new molecular glue degraders (MGDs) for multiple targets across oncology and immunology, with the deal worth $1.64bn. The collaboration and option-to-licence agreement combines AbbVie’s capabilities in oncology and immunology drug development with Neomorph’s molecular glue discovery platform.
AbbVie and Neomorph link on oncology/immunology glue degraders
AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology. Tailored to selectively target and induce the degradation of proteins associated with disease progression,
Sticky, sticky, sticky: Neomorph tacks on another Big Pharma glue degrader deal with $1.6B AbbVie pact
Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform. | Neomorph is building out its supply of Big Pharma partnerships,
AbbVie and Neomorph to codevelop molecular glue degraders for onchology
AbbVie (ABBV) and Neomorph announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple
AbbVie, Neomorph partner on protein degrader drugs
NORTH CHICAGO, Ill. - AbbVie (NYSE: NYSE:ABBV), a prominent player in the biotechnology industry with a market capitalization of $299 billion, and Neomorph, Inc. have entered into a collaboration to develop a new class of drugs known as molecular glue degraders,
AbbVie, Neomorph to develop molecular glue degraders
AbbVie (NYSE:ABBV) has entered into a collaboration agreement with Neomorph for the development of novel molecular glue degraders for multiple targets across oncology and immunology. Under the deal, Neomorph will receive an upfront payment and is eligible to receive up to $1.
AbbVie To Collaborate With Neomorph To Develop Molecular Glue Degraders For Oncology And Immunology
AbbVie, Inc. (ABBV) and Neomorph, Inc. announced Thursday a collaboration and option-to-license agreement to develop novel molecular
Monte Rosa Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Detailed price information for Monte Rosa Therapeutics Inc (GLUE-Q) from The Globe and Mail including charting and trades.
AbbVie and Neomorph Announce Collaboration to Develop Molecular Glue Degraders for Oncology and Immunology
AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple targets across oncology and immunology.